Introduction
============

Myopia, the most common eye disease worldwide, is also the leading cause of visual impairment \[[@r1]\]. The prevalence of myopia has been increasing in recent decades, especially in East Asian areas such as Japan, Singapore, and China \[[@r2]-[@r4]\]. The Chinese appear to be more susceptible to myopia than other populations. The prevalence of myopia in primary school children aged 5 to 16 years of Hong Kong is 36.71% \[[@r5]\]. In adult persons more than 40 years old, Chinese residing in Singapore have a prevalence of myopia as high as 38.7% while the prevalence observed in European-derived populations in United States and Australia are 26.2% and 17% respectively \[[@r3],[@r6],[@r7]\]. High myopia, which is defined as a refractive error equal to or below −6.00 diopters (D), is also more prevalent in Chinese than Caucasian populations \[[@r3],[@r8]\]. Individuals with high myopia have a greater chance of subsequently developing serious complications, including glaucoma, retinal detachment, and choroidal neovascularization, which if not treated early and appropriately, may lead to permanent visual impairment or blindness \[[@r9]-[@r11]\].

Genetic and environmental factors both contribute to the development of myopia. Environmental factors such as work at close range and prolonged reading are suggested to be involved in the progression of myopia \[[@r1],[@r12],[@r13]\] and a body of evidence supports the idea that heredity plays a central role in the etiology of myopia. Twin studies have reported a high degree of heritability for myopia, with monozygotic twins being more highly correlated than dizygotic twins \[[@r14],[@r15]\]. In addition, the children of parents with myopia tend to have myopia more frequently than children of parents without myopia \[[@r16]\].

The inheritance of high myopia is equivocal. It may be inherited as an autosomal dominant, autosomal recessive, or X-linked recessive trait. Genetic mapping studies have identified at least 18 chromosomal regions suspected of harboring a myopia gene. X-linked recessive inheritance myopia has been mapped on Xq28 (MYP1) and Xq23--25 (MYP13) \[[@r17],[@r18]\]. In addition, Yang et al. \[[@r19]\] found that the locus at 14q22.1-q24.2 (MYP18) was responsible for high myopia in a consanguineous Chinese family in an autosomal recessive pattern. Some research groups focusing on autosomal dominant high myopia have identified suggestive linkages on chromosome 18p11.31 (MYP2) \[[@r20]\], 12q21--23 (MYP3) \[[@r21]\], 7q36 (MYP4) \[[@r22]\], 17q21--22 (MYP5) \[[@r23]\], 4q22-q27 (MYP11) \[[@r24]\], 2q37.1 (MYP12) \[[@r25]\], 10q21.1 (MYP15) \[[@r26]\], and 5p15 (MYP16) \[[@r27]\]. Furthermore, certain loci have also been implicated in common myopia: 22q12 (MYP6) \[[@r28]\], 11p13 (MYP7), 3q26 (MYP8), 4q12 (MYP9), 8p23 (MYP10) \[[@r29]\], 1p36 (MYP14) \[[@r30]\], and 7p15 (MYP17) \[[@r31]\]. Identifying the genetic markers for myopia would be a useful step toward understanding the molecular defects that lead to the pathophysiology of myopia.

In this study, we recruited a four-generational Chinese family with autosomal dominant high myopia. Through genome-wide screening and linkage analysis, we mapped the disease to a locus on chromosome 5p13.3-p15.1.

Methods
=======

Family and clinical evaluation
------------------------------

A large family with autosomal dominant high myopia was identified in Zhejiang province, China. This family contained 11 affected individuals over four generations. Participating in this study were 29 individuals (aged 11 to 80 years): 10 affected and 19 unaffected ([Figure 1](#f1){ref-type="fig"}). The study conformed to the guidelines involving human research as stated in the Declaration of Helsinki. Informed consent was obtained from every subject after an explanation of the nature, procedures and possible consequences of the study. This family was chosen based on the presence of numerous male and female family members and successful multiple generations with high myopia, suggesting an autosomal dominant mode of inheritance. Individuals with a spherical refractive error equal to or lower than −6.00 D, axial length longer than 26 mm in at least one eye and a history of myopia onset before 12 years of age were considered affected. Ophthalmology examination was performed for all of the members. No participant had any known ocular disease or insult that could predispose to myopia, such as a history of retinopathy of premature or neonatal problems, or a known genetic disease or connective tissue disorder associated with myopia, such as Stickler or Marfan syndrome. The results of the ophthalmic examinations are summarized in [Table 1](#t1){ref-type="table"}.

![Pedigree and haplotype diagram of the family. Circles and squares denote females and males, respectively; blackened symbols denote affected individuals; a diagonal line through a symbol means that the individual is deceased. Haplotypes were constructed on the basis of the minimum number of recombinations between these markers. Solid bar: the chromosome assumed to carry the inherited disease allele; open bar: normal haplotypes. Only essential members are shown; nonparticipating family members were excluded. For individuals IV:2, only one set of parental-allele information was available; therefore, the genotype information was indeterminate (denoted by question marks) for markers D5S416 and D5S385. Individual III:17 was recombinant for the telomeric marker D5S2096. Individuals III:7 and III:11 were recombinant for the centromeric marker D5S1986.](mv-v16-2043-f1){#f1}

###### Clinical information of individuals in the family.

  **Subject**   **Gender**   **Myopia phenotype**   **Age at onset (years)**   **Age at exam (years)**   **Refractive Error OD**   **Refractive Error OS**   **Axial Length (OD;OS \[mm\])**
  ------------- ------------ ---------------------- -------------------------- ------------------------- ------------------------- ------------------------- ---------------------------------
  II:1          F            A                      7                          80                        −11.00DS −4.00DC×100      −16.00DS −2.00DC×105      29.24; 30.10
  II:5          F            A                      8                          79                        −10.50DS −0. 50DC×90      −12.00DS −2.00DC×100      27.92; 27.57
  III:1         M            NA                                                45                        +1.00DS +1.00DC×180       +1.00DS +1.00DC×180       NP
  III:2         F            A                      11                         43                        −2.50DS −0.50DC×40        −11.50DS −1.50DC×150      22.62; 26.80
  III:3         M            NA                                                49                        +0.50DS sph               +0.50DS +0.50DC×180       23.04; 23.01
  III:5         M            NA                                                55                        +0.75DC×180               +0.75DC×180               24.11; 24.20
  III:6         F            NA                                                48                        +1.00DS +0.75DC×180       +1.00DS +1.00DC×180       22.82; 22.59
  III:7         M            A                      6                          41                        −24.00DS −2.00DC×40       −26.00DS −2.00DC×120      31.42; 31.18
  III:8         M            NA                                                46                        −4.50DS −0.50DC×90        −3.50DS −0.50DC×90        25.40; 25.51
  III:9         F            A                      11                         43                        +0.50DS −1.50DC×40        −15.50DS −1.50DC×140      22.92; 28.81
  III:10        F            NA                                                37                        +0.50DS +0.50DC×20        +1.00DS sph               22.61; 22.03
  III:11        M            A                      6                          40                        −16.00DS −1.00DC×60       +0.50DS −2.50DC×160       31.21; 25.60
  III:12        F            NA                                                36                        +0.50DS sph               +0.50DS sph               22.72; 22.49
  III:13        M            A                      5                          45                        −10.00DS sph              −9.00DS −1.00DC×120       29.40; 29.32
  III:14        F            NA                                                36                        +1.00DS −0.50DC×180       +1.00DS sph               23.41; 23.02
  III:15        M            NA                                                41                        +0.50DS sph               +0.50DS sph               23.42; 23.57
  III:16        F            NA                                                39                        +0.75DS sph               +0.75DS sph               23.02; 23.11
  III:17        M            A                      5                          46                        −17.00DS sph              −15.00DS sph              29.54; 31.56
  III:18        M            NA                                                58                        +1.00DS +1.00DC×180       +1.00DS +0.50DC×180       23.78; 23.81
  III:19        F            NA                                                58                        +1.00DS +0.75DC×180       +1.00DS +0.50DC×180       22.45; 22.37
  IV:1          F            A                      6                          15                        −13.00DS −3.00DC×10       −10.00DS −5.00DC×165      28.27; 27.73
  IV:2          F            NA                                                25                        −0.75DS sph               −0.50DS sph               23.30; 23.02
  IV:3          F            NA                                                28                        −5.50DS sph               −5.50DS sph               25.41; 25.50
  IV:4          F            NA                                                17                        −4.25DS −1.00DC×170       −5.00DS −1.00DC×170       25.55; 25.72
  IV:5          F            NA                                                11                        +0.50DS sph               +0.50DS sph               22.31; 22.49
  IV:6          M            NA                                                16                        −1.00DS sph               −1.00DS sph               24.41; 24.29
  IV:7          M            NA                                                13                        +0.50DS sph               +0.50DS sph               23.95; 23.86
  IV:8          M            NA                                                30                        +1.50DC×90                +1.75DC×90                22.67; 23.93
  IV:9          M            A                      4                          32                        −6.50DS −2.25DC×30        −8.00DS −2.00DC×170       28.03; 27.81

In the table, "A" indicates affected; "NA" indicates not affected; "M" indicates male; "F" indicates female; "OD" indicates right eye; "OS" indicates left eye; "NP" indicates not preformed; "sph" indicates sphere; and "mm" indicates millimeters.

Genotyping and linkage analysis
-------------------------------

Genomic DNA was isolated from peripheral blood leucocytes by the standard proteinase K digestion and phenol-chloroform extraction. The genome-wide screen was conducted on ABI 3700 sequencer by using PRISM Linkage Mapping Set MD-10 (Applied Biosystems, Inc., Foster City, CA) that have 382 highly polymorphic fluorescent markers with an average spacing of 10 cM. The markers were ampliﬁed by polymerase chain reaction (PCR) under the following conditions: 50 ng genomic DNA, 2 pmol each primer, 0.2 μl dNTP (10 mM each), 1 μl 10× buffer, 0.6 μl MgCl~2~ (25 mM) and 0.4 U HotStar Taq DNA polymerase (Qiagen, Santa Clarita, CA) in a ﬁnal volume of 10 μl. Six to eight primer pairs were multiplexed in the ampliﬁcation reaction. Samples were incubated in a PTC-225 DNA Engine Tetrad (MJ Research, Waltham, MA) for 15 min at 95 °C to predenature, followed by 35 cycles of 30 s at 94 °C, 40 s at 55 °C, 40 s at 72 °C, and a ﬁnal extension at 72 °C for 10 min. Ampliﬁcation products were appropriately pooled into prescribed panels, diluted, and denatured for 5 min at 95 °C, then incubated on ice for 2 min. Subsequently, the products were run in an automated DNA sequencer (ABI Prism 3700; Applied Biosystems).

Data were analyzed using GeneScan 3.7NT and Genotyper 3.7NT software (Perkin Elmer, Foster City, CA). Two-point LOD scores were calculated using the [MLINK](http://linkage.rockefeller.edu/soft/fastlink) program from the Linkage software package (version 5.2). For fine mapping, additional microsatellite markers spanning the chromosome 5p region were selected from the genetic map of the Marshfield Center for Medical Genetics (Marshfield, WI). The myopia in the family was analyzed as an autosomal dominant trait with 90% penetrance and with a disease-gene allele frequency of 0.01. Recombination frequencies were assumed to be equal between males and females. Haplotype analysis was performed with [Cyrillic](http://linkage.rockefeller.edu/soft/fastlink) software (version 2.0) and confirmed by inspection.

Positional candidate gene mutation screening
--------------------------------------------

The identiﬁed genes located in the linkage region were proposed as candidate genes on the basis of their functional information. Mutations of these genes were screened by direct sequencing. Using the soft Primer Express 2.0 (Perkin Elmer), primers were designed to amplify each exon including exon-intron boundaries regions of the candidate genes from genomic DNA (the sequences of all primers used in this study are summarized in [Table 2](#t2){ref-type="table"}). Screening for mutations was initially performed in two affected and two unaffected individuals. The PCRs were performed using Taq DNA polymerase and the products were sequenced directly with a dye-terminator cycle-sequencing system by ABI Prism 3700 DNA sequencer after puriﬁed by exonuclease I (Epicenter, Madison, WI) and shrimp alkaline phosphatase (USB, Cleveland, OH). The resulting sequences were compared with the corresponding wild-type sequences using Autoassembler software (version 2.0; Perkin Elmer). When a sequence variant was detected, the exon was ampliﬁed from the genomic DNA extracted from the other individuals to determine whether the base variant was speciﬁc to the patients. The NCBI [SNP](http://www.ncbi.nlm.nih.gov/snp) database was also referenced to determine whether the sequence variant was a polymorphism.

###### Primers designed for mutation screening.

  Exon        Primer Sequence (F,R)          Melting Temperature (°C)   Product Size (bp)
  ----------- ------------------------------ -------------------------- -------------------
  *CDH6*                                                                
  1           F:CAGACGGAGTCATACAAGTTCTGAG    58                         824
              R: GCCCTTTGGTAATTGACCAGC       59                          
  2           F:GCACATGCCTTCCATTTAGC         57                         770
              R: GGTTGTGGGTGTTTCAACTGG       59                          
  3           F: CTCCCAAACTCTGTTCCAGTTC      57                         775
              R: TCTCTTTCAACCTCCCACTCC       57                          
  4           F: CCAAAGTTCTCGACTTCCTCAG      57                         369
              R: GTGTTTGGTGGATGTATGCAAG      57                          
  5           F: ATCTATCTCCCCTGTGTGGTTG      57                         521
              R: TTCCTGAGTGTATGCCATGTTG      57                          
  6           F: AAGAAGAACAGGCCACCATTAG      56                         583
              R: GGTTTTGCCATGTTGGTCTC        57                          
  7           F: CATTTTTCAGGGCTGTGTGG        58                         592
              R: CATCTTTTCTCAAGTGCAGGC       56                          
  8           F: GGTGATCTTCAAAGTCATGCAAC     57                         538
              R: GAAACATTACTGCAAACCACTCC     57                          
  9           F: GTCTAAAGGGAATCGGCAATC       56                         397
              R: TGGAATCAGCCTCAGTCTTTG       57                          
  10          F: TACTGATATCTCGTGGGTAGAGGC    58                         552
              R: GCAAAGTGGTGAATGTATGTGG      57                          
  11          F: GCCAGTGGCTCAAACTTTACC       57                         573
              R: CAGGCTGTATGCCTTAATGGG       58                          
  12          F: ATCATGGATGGAGGCAAGTG        57                         756
              R: AACGGGTAGAACAGAGAAGCC       58                          
  *CDH10*                                                               
  1           F: CTATCAGCAGAACCTTTCTCTCCG    60                         562
              R: CAAACATTTATCTCCTCCCTCTCC    58                          
  2           F: CACAACAGAAGGCGTGATTCC       59                         603
              R: TGCTTCCTCACTGAACTCAATAGC    59                          
  3           F: TTTACCAAGCAAAGACAGGAGC      57                         672
              R: CTCATGGTAGCAAATCAAAGAGG     57                          
  4           F: TTGCTCCTCCTTCTGGTACTGTG     59                         626
              R: TTCATGTTCGGTAAAGCAGTCC      58                          
  5           F: GTGGTATTGCTAGGAAAGGGTAAC    56                         600
              R: GGATCATAGGTCTTCCTGTCTCTG    57                          
  6           F: AAAAGCCCCGGAAGTTCCTAG       60                         611
              R: CAGGTTTCCTGTCTCAATCAACC     59                          
  7           F: TGTAACTGGGTGGGAGCATATC      58                         467
              R: AGTAGAGACAGGGTTTCACCATG     56                          
  8           F: TCAGTGATATGTGTGGGTTTGC      57                         521
              R: CGGCCTGTTAATCTGTTTCATG      58                          
  9           F: CACTTCATACCCACAAGATGCC      58                         577
              R: GCATTCGTCTCTCATCTCTCTAGC    58                          
  10          F: TAAAGGGTATGATCCAAAAGACAC    56                         587
              R: ATCTCCAGCCGTTCTAATCTTATC    56                          
  11          F: GTAAGCACACACGCACAGATG       56                         997
              R: TTTCCAAGCTCCTACACATGC       57                          
  12-1        F: TGCTAAACCCTTCAGCGTCTC       58                         779
              R: AAATTGTGCTGACTGGCAGG        57                          
  12-2        F: TCCATTGCTGAATCTCTGAGTTC     57                         889
              R: CATAGCATATCAAGACTCGCTGG     58                          
  *CDH12*                                                               
  1           F: CAGGTGACAGTTCTCTGATATGC     55                         679
              R: ATCCCAATCAAAAACGGAAG        55                          
  2           F: CAATAGTGATAATCAGGTGTGAGG    58                         398
              R: TTGTTGTGTTTATGTCAACTCCTTG   57                          
  3           F: TGCTGATTAGGATGTGGGC         56                         403
              R: TCCAGTCTGGGTGAAAGAGTG       56                          
  4           F: AGCGTTCTTGCTAATCAGGTC       55                         367
              R: GAAATTCAGTGCCATGCAGTC       57                          
  5           F: GGCAGATATAATGAGCGTTGTG      56                         537
              R: CCTTCCTATCAAGCGGTTGTC       57                          
  6           F: TGGCACATCCTTTTAATGGTG       57                         421
              R: TGTTGAAGAGGTCTCATTGTATCTC   55                          
  7           F: CGAGTCCAGCAGATAAGAGTCATG    59                         233
              R: GGCTGGTGATAATGTTGCCTC       58                          
  8           F: ATATTTCTCATTGTGGCATGGC      58                         511
              R: GCTTCCTAAAGACTAAGTGTCTGG    57                          
  9           F: GCCCAGTTAAAATTCTAGAGCAGC    59                         560
              R: CACGGAGTATCAGTACCCCAAC      57                          
  10          F: TCACCATTTCTGCCACATTC        56                         414
              R: CATCATGCAGTTTTGGACAGAG      57                          
  11          F: TTTCCCCTTGAGCATACTGAC       56                         399
              R: GAAAAACATCTCAGCAGGGAC       55                          
  12          F: TGTAGAAGCAATAACTGACCGG      56                         384
              R: TCATCTGTGCGGTATCACCTC       57                          
  13          F: CCTCTTTGAAACTGATGACCG       56                         366
              R: ACAATGCAAGCAACCTGCC         58                          
  14          F: CTATTGAGCAGATACCAACTTGAAG   55                         385
              R: AAAAAAAGGAAGAGAGAGCGAG      55                          
  15-1        F: CATTCACGAAACTCAGCCAC        55                         521
              R: GATAGTCATAGTCCTGGTCGGC      56                          
  15-2        F: CTGCCCCACCATACGATTC         57                         494
              R: ATAGGCCTGAGCTTGTCTCAG       55                          
  15-3        F: TCTGCCAACAAGAGATACATCC      57                         632
              R: ATTTGAGCCCTGAGGCCTC         58                          
  *PDZD2*                                                               
  1-1         F: CTCTTCCTCTCCCAGGTGTGA       58                         410
              R: AGGTGCAGCACGGCATTG          60                          
  1-2         F: AGCCTGAACATGAACACAGGC       59                         776
              R: TGGTGCTCCAGTTGAAGATGTG      60                          
  2           F: AAGCTCAATACCTCAGTCCATCG     58                         720
              R: CAGCTTGTATTTCCCGCATG        58                          
  3           F: CCAGTTGCCACTAGCCACATC       59                         615
              R: TGTGCTCAGAGGTGTGTTCAATT     58                          
  4           F: AACAATCGCATCCCCAACTG        59                         587
              R: TGCGCCATTGCACTCCAG          61                          
  5           F: CCTGGCCTTTGAGGTAACCTT       58                         425
              R: TGGTGTCTTTTCCCATCATGGT      60                          
  6           F: GGAATTGGCCAATGCAAGG         60                         671
              R: TTGCTCCAAAAGCTGCAACTC       59                          
  7           F: GCCTGACACTAATGGCTTCAGC      60                         630
              R: CTATGAGACGCCATCGTCTCC       58                          
  8           F: TTTATTAGAGCCGGGGTTTCAC      58                         639
              R: TGCAATGGCTCATGCCTATAATC     60                          
  9           F: TTAACTCCAGGCCTGGTTAGGG      60                         592
              R: CCAGCCCTAAGGTAAGAATGGAC     59                          
  10 and 11   F: GTGACATTCCTGGGAGCTAAGCTA    60                         816
              R: AGAGCTCCATGCTACTGGTAACTTC   58                          
  12          F: GCCATGGGCTCATTCTATTAACAG    60                         529
              R: GGGAAGCCAAGATCTAGAGTTCTC    58                          
  13          F: GCATAATGACCTTTGCCCACTT      59                         575
              R: CTTACCTCCCACCAGACAAGTTTC    59                          
  14          F: GGAGGATGGTCATAATCCTTGG      58                         691
              R: CTATCTCAAGCCTTCTCTGCCTG     58                          
  15          F: CTGGGATCATCATGCAGGTAGTAG    59                         584
              R: TAAAGCCCCAAGTCCTGACTCAC     60                          
  16          F: GTTGTCAATTTAGCCGTTCTGAG     57                         579
              R: AGTAGAGATGGGGTTTCACCATGT    59                          
  17-1        F: AGCCATGTTGCCTAGGCCTT        60                         583
              R: CCATGCCCTCTGGGATACTC        58                          
  17-2        F: GACAGAGAAGGGGACTGCATT       57                         725
              R: CCAGCCATCATCCTTTCCC         59                          
  18          F: TGGATCTGCTGGCTCCTAGTC       58                         430
              R: TCTCAAACTCCTGACCTCAAGTG     57                          
  19-1        F: GCTGGTCTCGAACTCCTGACC       60                         657
              R: AGGTGCATGGATTCCTGTCATT      59                          
  19-2        F: ACAATACCAGGAGGGTGGCTG       60                         820
              R: CTTGTGCAAAGACACACGGG        59                          
  19-3        F: GACAGCACCTCCCTATCAGGC       60                         800
              R: CATGATGGGCCTCCTAGCG         60                          
  19-4        F: GCATTAATGCAGCTGCCAGTC       59                         705
              R: GCGAGACAAATGTCCTGATGC       59                          
  19-5        F: TGACAGAAACACCACAGCTGC       58                         721
              R: GTATTCTGCCTTTCTAATGGCTG     56                          
  19-6        F: AATCAGGCTCTATCGCCAGGT       59                         630
              R: ATCCGCTGCTTCACAGAGAA        57                          
  19-7        F: TATATAGTGTAAAGCCGCTGCTGG    59                         779
              R: TGGGAACTCTGCATTATCTTTGC     59                          
  20          F: ATTCATAGCAGTTCCCCTTGCC      60                         520
              R: CTGAAGCTGGCTAGCAGCAC        58                          
  21          F: AGAACCTTTAGGGCCTGTGG        57                         638
              R: AAGGTGACCCTCTGGATGGTC       59                          
  22          F: GAGGCTGAGATTGCACCACTG       59                         765
              R: CCTTACCAGTCCTAACAAGAGGC     57                          
  23          F: AGTGCTACTGGGCTCAAGTGC       58                         511
              R: GGGATAATGATGACACCCACC       57                          
  24-1        F: ACAGATTATGTTTGGAGGGGC       57                         675
              R: TCACATCTTGTATCCCCATCAGTA    57                          
  24-2        F: TGTGCAACAGCAATGAAATTAAC     56                         732
              R: TGCTCTTGGACTGACCAGTC        55                          
  24-3        F: TAGAGGGAGCAGAAAGGTCAACA     59                         771
              R: TCATGCACACAGGTATGGCAA       60                          
  24-4        F: GTAAAGGAGCAGAAATGTAGTTACA   56                         722
              R: AGGTCTACCCTTGTACTCCAGATAT   55                          
  24-5        F: TTAATTAATAAACGCACAGCCCTA    56                         844
              R: GTACCTCTGATGCATTTAGGTGAC    56                          
  *GLOPH3*                                                              
  1           F: TAATTAACTCCCGCGCCGA         60                         776
              R: GGGGAGGATCCAGAAAGCA         59                          
  2           F: TGGGGTTAACTGAGTATTCCTTGG    59                         814
              R: TATTGTCCTGTGACCCTGCCA       60                          
  3           F: GCTACTGAGTCTAGCCAATTTTCAT   56                         637
              R: TACCACCACAGCTTAACCTAGCC     58                          
  4-1         F: GGTCTGGCTAGGCTTAAGGGG       60                         613
              R: GAATGGTTCACCCCGAGCA         60                          
  4-2         F: AAGAGAGTGCGGCAGCTTCTC       60                         734
              R: CCCATCCCAAACTGGCTCT         58                          
  4-3         F: GGCCTTCAACTCACCAAAGGTA      59                         679
              R: TACATGCAACATCTGCTAGGACTG    58                          
  4-4         F: GGCTTGTGACCAGTACCAATCT      57                         578
              R: AAACACAAATGACATGCTTGCTC     58                          
  *ZFR*                                                                 
  1 and 2     F: TTAAGGAGCCGCGAAGACG         60                         664
              R: TTCGTCGCATCGACAGGAT         59                          
  3           F: GACCTTTTGTGGTCCGTCATT       57                         578
              R: GGTATGTCCCAAACTACCAAGG      56                          
  4           F: GCCAGGATGGTCTTTATCTGCT      58                         664
              R: CAGCTTATTTCAGCAGGAATGG      58                          
  5           F: GGAGAAATTGCTGGCATAAAAT      56                         603
              R: CTAAGCCCAAGACTCATAATGAGC    57                          
  6           F: AAGGTTCTTCAAGGCAGGGAC       58                         667
              R: CCCTGAAAATTCTCATGCCAC       58                          
  7           F: CGGGCGATACAGAGAACCATAG      59                         568
              R: GACAGGTCTCCAGTCTTTCCCTC     59                          
  8           F: GAGGGAAAGACTGGAGACCTGTC     59                         893
              R: AGGGTCTTTGTGTGTGCAGATC      58                          
  9           F: GATGAGGAGGGTGTTGGGTG        59                         675
              R: TGCACACCACAGTGGCAATAC       59                          
  10          F: GAGGTTGTAGTGAGCTGAGTTCAA    56                         486
              R: AACCAAACATCCATCTGAGTCTAC    55                          
  11          F: TACATGTAGATTGTTTTGGGGC      55                         492
              R: TTGTTTGAAACCGAGGCACT        57                          
  12          F: TGGGAAGAAATTTTAGCTAGGCTG    59                         516
              R: AAGCTGAGGCAGGAGAATTGCT      60                          
  13          F: GGTGTACATGCATGCATGCAT       59                         569
              R: TGCAAGCAGCTGCAGAATACAT      60                          
  14          F: GATGGAAATTTTAATGGCACAAA     57                         573
              R: TCCTAACAACTGCCTTCTTATGAT    55                          
  15          F: AATAATACTGGCATGTACGGCAG     57                         406
              R: ATGCCAGCATGTTGCCTTCTA       59                          
  16          F: GGCTCATGTGACACTGATGCTAC     58                         366
              R: GCAATATGCAGATCATCATACCC     57                          
  17          F: CTGAGCTTCCATTGAACGGTG       59                         335
              R: CCCAGGATTTTTCATCAGAAAAG     58                          
  18 and 19   F: GATTACAGACGTGAGCCACTGTG     58                         666
              R: TCTAGGGGCTTGCTTACTACAGA     56                          
  20-1        F: TAGGTTGCATTTGGAGGGAGG       60                         774
              R: CAAACTCTGCAGTCTCACGTTACA    58                          
  20-2        F: CGAGATGGTATCCTTTACCCC       56                         570
              R:CACACCAATAAGGAACTGTCACC      57                          
  20-3        F: CTTGTGTATAAGTGGAAAGGGCA     57                         594
              R: GGCCGTGCTTAGACAACAAAC       58                          

Forward and reverse primers designed for *CDH6*, *CDH10*, *CDH12*, *PDZD2*, *GLOPH3*, and *ZFR* for mutation screening.

Results
=======

A large, multigenerational, Chinese family with autosomal dominant high myopia was recruited and characterized ([Figure 1](#f1){ref-type="fig"}). DNA was extracted from 29 blood samples of the family members (10 affected). The average age at diagnosis of myopia in the affected individuals was 6.9 years (range, 4 to 11 years). The average spherical component refractive error for the affected individuals was −11.59±5.26 D (range, −6.5 to −26 D). The mean axial lengths were 29.17±1.50 mm (range, 26.80 mm to 31.42 mm) and 23.59±1.04 mm (range, 22.03 mm to 25.72mm) for highly myopic and non-highly myopic subjects, respectively. Individual III:7 had the highest refractive error of −24.00 D for the right eye and −26.00 D for the left eye ([Table 1](#t1){ref-type="table"}).

Ophthalmological examination excluded known ocular diseases associated with myopia, including keratoconus, spherophakia, ectopia lentis, retinal dystrophy, and optic atrophy. Males and females in this family were equally affected.

All known syndromic myopia loci were excluded in this family. The LOD scores at θ=0.00 were as follows: D15S117 (Marfan syndrome), −2.43; D1S218 (juvenile glaucoma), −2.5; D12S85 (Stickler syndrome type 1), −6.44; D1S206 (Stickler syndrome type 2), −10.77; and D6S276 (Stickler syndrome type 3), −4.15. Linkage to all of the known loci for non-syndromic autosomal dominant high myopia showed no statistically significant or suggestive evidence of linkage in this family (data not shown). Through subsequent genome-wide screening, a two-point LOD score of 3.02 (θ=0.00) was initially obtained with the microsatellite marker D5S419, suggesting that the causative locus for the family with high myopia was mapped to a region adjacent to D5S419 on chromosome 5. For fine mapping, an additional 13 closely flanking microsatellite markers were tested, and the linkage analysis resulted in a significant LOD score at 5p13.3-p15.1. Seven microsatellite markers displayed positive LOD scores, with D5S502 having the highest LOD score, 3.71 at θ=0.00 ([Table 3](#t3){ref-type="table"}).

###### Two-point linkage analysis between high myopia and markers on chromosome 5p13.3-p15.1.

                            **LOD Score at θ=**                                                           
  --------- ------- ------- --------------------- ------- ------- ------- ------- ------- ------- ------- ------
  D5S416    28.76   16.74   −2.58                 −1.72   −0.72   −0.17   0.27    0.33    0.21    0.33    0.30
  D5S486    31.78   17.20   −3.60                 −1.91   −0.61   0.00    0.44    0.46    0.28    0.46    0.30
  D5S2096   33.04   17.47   −1.33                 −1.13   −0.59   −0.22   0.10    0.14    0.05    0.14    0.30
  D5S2074   36.25   21.15   2.00                  2.02    2.01    1.92    1.57    1.07    0.46    2.02    0.01
  D5S813    37.32   23.48   2.86                  2.81    2.60    2.35    1.83    1.22    0.53    2.86    0.00
  D5S502    39.46   25.57   3.71                  3.67    3.48    3.20    2.53    1.73    0.80    3.71    0.00
  D5S419    39.99   26.54   3.02                  2.99    2.84    2.61    2.05    1.37    0.60    3.02    0.00
  D5S385    39.99   27.34   1.92                  1.87    1.68    1.45    0.99    0.52    0.12    1.92    0.00
  D5S2061   41.06   29.86   1.69                  1.66    1.52    1.34    0.99    0.58    0.21    1.69    0.00
  D5S819    41.06   30.75   2.23                  2.22    2.05    1.83    1.36    0.86    0.37    2.23    0.00
  D5S1986   44.73   31.61   −5.03                 −1.53   −0.14   0.36    0.61    0.50    0.25    0.61    0.20
  D5S1470   45.34   32.37   −1.41                 −0.83   0.27    0.66    0.80    0.62    0.29    0.80    0.20
  D5S674    47.09   33.42   −3.43                 −1.77   −0.99   −0.60   −0.18   0.01    0.07    0.07    0.40
  D5S426    51.99   34.64   −6.00                 −5.06   −3.16   −1.99   −0.82   −0.28   −0.04   −0.04   0.40

Fine mapping demonstrated strong evidence of a suggestive linkage for a locus between D5S2096 and D5S1986 on chromosome 5p13.3-p15.1. LOD scores were generated using a dominant mode of inheritance with 90% penetrance and with a disease-gene allele frequency of 0.01.

Haplotype analysis of the affected individuals revealed recombination events that narrowed the region containing the gene, as shown in [Figure 1](#f1){ref-type="fig"}. Through haplotype analysis, it was discovered that in addition to the ten affected individuals, two unaffected siblings (III:15 and III:19) also inherited the putative disease allele. At the time of examination, III:15 and III:19 were 41 and 58 years of age, respectively, and it was not likely that they would develop high myopia. Interestingly, III:15 had only read for 5 years in primary school and III:19 had never attended school: both of them had spent less time reading.

The critical region was found to be between the markers D5S2096 and D5S1986. A telomeric recombinant event occurred between markers D5S2096 and D5S2074 in the affected individual III:17, which defined the distal limit of the region to marker D5S2096. Affected individual IV:9 displayed evidence of a centromeric recombinant event between markers D5S1986 and D5S1470. Another centromeric recombination event was observed between markers D5S819 and D5S1986 in two affected individuals, III:7 and III:11. These defined the proximal limit of the region to marker D5S1986. Ultimately, we mapped high myopia to a locus on chromosome 5p13.3-p15.1, covering an approximately 11.69 cM (14.14 Mb) region between D5S2096 and D5S1986.

Within the linkage region, the six genes cadherin 6, type II (*CDH6*), cadherin 10, type II (*CDH10*), cadherin 12, type II (*CDH12*), PDZ domain-containing protein 2 (*PDZD2*), Golgi phosphoprotein 3 (*GOLPH3*), zinc finger RNA binding protein (*ZFR*) were selected as candidate genes on the basis of their function: cell adhesion, intracellular signal transduction, protein trafficking, and DNA/RNA binding activities, which we thought were the functions most likely to be associated with myopia. A description of these genes was provided in [Table 4](#t4){ref-type="table"}. However, mutation analysis did not reveal any disease-causing mutation.

###### Description of candidate genes located in the linkage interval of 5p13.3-p15.1.

  **Symbol**   **Full name**                         **Function**                                                        **Cellular component**
  ------------ ------------------------------------- ------------------------------------------------------------------- ------------------------
  *CDH6*       Cadherin 6, type II (K- cadherin)     Cell adhesion, development, neuron adhesion                         Cytoplasm
  *CDH10*      Cadherin 10, type II (T2-cadherin)    Cell adhesion, development, neuron adhesion                         Cytoplasm
  *CDH12*      Cadherin 12, type II (Br- cadherin)   Cell adhesion, development, neuron adhesion                         Cytoplasm
  *PDZD2*      PDZ domain-containing protein 2       Intracellular signal transduction, Control plasticity of synapses   Cytoplasm
  *GOLPH3*     Golgi phosphoprotein 3                Regulate protein trafficking                                        Cytoplasm
  *ZFR*        Zinc finger RNA binding protein       DNA and RNA binding, DNA repairing activity                         Nucleus; Cytoplasm

Discussion
==========

In this study, a locus for autosomal dominant high myopia in a large Chinese family was identified. Genome screening and linkage analysis located a critical region for high myopia on chromosome 5p13.3-p15.1 between D5S2096 and D5S1986, within an 11.69 cM interval. Linkage to the candidate gene regions for the Stickler syndromes, Marfan syndrome, and juvenile glaucoma was excluded, ensuring that this family did not exhibit a mild phenotypic expression of these conditions. Similarly, linkage was excluded from known autosomal myopia loci. This study has provided additional evidence for the genetic heterogeneity of autosomal dominant high myopia.

Myopia is thought to be multifactorial, caused by a variety of environmental and genetic factors as well as their interactions. Compared to the remarkable progress in identifying the genes for retinal degeneration, genes causing non-syndromic myopia (common or high) have proven difficult to identify. The likely explanation for this difficulty is that the gene-environment interplay affects even Mendelian patterns of myopia \[[@r1],[@r12],[@r13]\]. The underlying pattern of genetic and/or environmental factors in myopic subjects is highly variable and incomplete penetrance is common in high myopia, as reported in other high myopia families \[[@r26],[@r32]\]. It was noted that all patients with high myopia in this family carried the putative disease haplotype; but two individuals, III:15 and III:19, both of whom inherited the putative disease allele from their mother, did not have high myopia. At the time of examination, III:15 and III:19 were 41 and 58 years of age, respectively, and it was not likely that they would develop high myopia. Interestingly, III:15 had only read for 5 years in primary school and III:19 had never entered school, so these two siblings had spent less time reading. These suggested that the variability in the phenotype might be mostly attributable to the interplay of genetic and environmental factors, leading to incomplete penetrance of the disease.

Six candidate genes *CDH6*, *CDH10*, *CDH12*, *PDZD2*, *GOLPH3*, and *ZFR* at this high myopia locus were selected on the basis of their function to screen for gene mutations by re-sequencing. The classical cadherins mediate homophilic cell--cell adhesion and are key regulators of many morphogenetic processes \[[@r33]\].

Loss-of-function studies demonstrate that the classical cadherins play a crucial role in vertebrate retinogenesis. They have multiple morphoregulatory functions in retinal proliferation, migration, differentiation, and layer formation, as well as axonal outgrowth, pathfinding, target recognition, and synaptogenesis \[[@r34],[@r35]\]. *CDH6* regulates the differentiation of retinal ganglion cells, amacrine cells, and photoreceptors in Zebrafish \[[@r36]\]. *CDH10* and *CDH12* were detected in the mouse eye during the first postnatal week when several developmental processes, such as cell migration and formation of synaptic connections, occur simultaneously \[[@r37]\]. *PDZD2* is a ubiquitously expressed multi-PDZ-domain protein \[[@r38]\]. PDZ domain scaffolds have been shown by genetic, electrophysiological, and morphological studies to be essential for controlling the structure, strength, and plasticity of synapses, which may play a role in the process of vision formation \[[@r39]\]. *GOLPH3* is a peripheral membrane protein of the Golgi stack. It is required for trafficking from the Golgi to the plasma membrane and for the normal extended Golgi ribbon. Depletion of *GOLPH3* alters the Golgi ribbon, changing its normal appearance of extending partially around the nucleus, to condensing at one end of the nucleus \[[@r40]\]. *ZFR* contains three widely spaced zinc finger domains. Zinc finger proteins with a similar pattern of zinc finger motifs are known to bind RNA, DNA, and DNA/RNA hybrids \[[@r41]\]. *ZFR* can be involved in DNA repair and chromosome organization \[[@r42]\]. Analyses of *ZFR* knockout mice indicate that *ZFR* is essential for at least some developmental pathways, as embryonic death occurs at 8--9 days gestation in these mice. In homozygotes, genetic ablation of *ZFR* causes increased embryonic cell death and/or decreased cell proliferation rates \[[@r43]\]. In the current study, PCR and sequencing primers were synthesized for the exons and peripheral intron regions of these candidate genes, and direct sequencing analysis was performed. However, no disease mutation was identified.

A previous study revealed an autosomal dominant high myopia locus mapped to chromosome 5p15.33-p15.2 with an interval of 17.45 cM between D5S1970 and D5S1987 in three Chinese pedigrees originating from Hong Kong (HK) \[[@r27]\]. In our study, the locus for high myopia of the pedigree was mapped to the critical region between D5S2096 and D5S1986 on chromosome 5p13.3-p15.1. The physical distance of the two markers yielding the peak two-point LOD score (D5S2505 in HK families and D5S502 in Zhejiang family) is approximately 19.7 Mb. The physical distance of the nearest two markers displaying a strong linkage to high myopia in these two studies (D5S1987 and D5S2074) was 9.71 Mb. However, the linkage regions with high myopia on the short arm of chromosome 5 identified in these two studies did not show any overlap ([Figure 2](#f2){ref-type="fig"}). The fact that the two causative loci identified in these Chinese families with inherited high myopia did not overlap, but were adjacent, suggested that there may be disease gene(s) for high myopia on the short arm of chromosome 5 in the Chinese population. Although no mutation has yet been identified for the putative candidate genes, a more refined mutation screen is needed to identify the causative gene(s).

![The position relationship between the locus and MYP16 (5p15.33--15.2) on the short arm of chromosome 5. The upper three markers were identified in MYP16 locus 5p15.33--15.2: D5S2505 was the marker with the peak two-point LOD score 4.81. D5S1987 was the marker close to centromeric with positive LOD score while D5S817 was the next marker displaying negative LOD score. The lower three markers were identified in the present study (bold text): D5S502 was the marker with the highest two-point LOD score 3.71. D5S2074 was the first telomeric marker having positive LOD score. The physical distance between D5S2505 and D5S502 was approximately 19.7Mb and the physical distance between D5S1987 and D5S2074 was 9.71Mb. In addition, the physical distance of the nearest two markers displaying negative linkage to high myopia in these two studies (D5S817 and D5S2096) was 5.83Mb.](mv-v16-2043-f2){#f2}

In summary, we have mapped a genetic locus for autosomal dominant high myopia in a large Chinese family. Myopia is the most common eye disease. Identification of the mutant gene(s) for myopia potentially would advance the understanding of the causes of this common eye disorder, and may thus lead to methods for preventing or slowing its progression.
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